Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results - Annexon Biosciences



clinical pipeline
for diseases of the body, brain & eye

Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results

May 17, 2021

ANX005 Huntington’s Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 –

– ANX009 First-in-Human dose-ranging trial completed with data expected summer 2021 –

– Next generation drug candidates, ANX105 and ANX1502, on track to submit INDs by end of 2021 –

Current cash position sufficient to fund operations through 2023

SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced first quarter 2021 financial results and business highlights.

Recent Business Highlights

Annexon is advancing a portfolio of innovative C1q inhibitors to stop classical complement-mediated autoimmune and neurodegenerative disease processes at the start in several indications. Recent portfolio highlights include:

“We are pleased with the strong progress on our mission to deliver transformative therapies for patients suffering from complement-driven autoimmune and neurodegenerative diseases,” said Douglas Love, Esq., president and chief executive officer of Annexon. “Annexon remains on track for another exciting year, and looking ahead, is sharply focused on effectively executing our several clinical programs while advancing multiple next generation drug candidates and driving our beachhead strategy to rapidly expand our platform into mechanistically related indications.”

First Quarter 2021 Financial Results

About Annexon, Inc.

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a rigorous, biomarker-driven development strategy designed to improve the probability of technical success over shorter development timelines. For more information, visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: sufficiency of the company’s cash to fund operations; continuing advancement of the company’s innovative portfolio; timing of data from clinical trials and regulatory submissions; timing of completion of clinical studies and clinical development milestones; the company’s ability to deliver on its objectives; and the implementation of the company’s business model and strategic plans for its business and product candidates, including potential treatment indications and additional indications that the company may pursue. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of COVID-19 or other public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. 

Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)

    Three Months Ended
March 31,
    2021     2020    
Operating expenses:                  
Research and development (1)   $ 20,696     $ 10,217    
General and administrative (1)     5,452       2,239    
Total operating expenses     26,148       12,456    
Loss from operations     (26,148 )     (12,456 )  
Other income, net     142       115    
Net loss     (26,006 )     (12,341 )  
Accretion on redeemable convertible preferred stock           (279 )  
Net loss attributable to common stockholders   $ (26,006 )   $ (12,620 )  
Net loss per share attributable to common stockholders, basic and diluted   $ (0.68 )   $ (29.10 )  
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted     38,163,062       433,749    
(1) Includes the following stock-based compensation expense:                  
Research and development   $ 1,546     $ 325    
General and administrative   $ 1,416     $ 338    

Condensed Consolidated Balance Sheets
(in thousands)

    March 31,
    December 31,
Current assets:                
Cash and cash equivalents   $ 206,669     $ 268,565  
Short-term investments     119,985       82,641  
Prepaid expenses and other current assets     3,868       2,805  
Total current assets     330,522       354,011  
Restricted cash     1,166        
Property and equipment     1,429       1,935  
Total assets   $ 333,117     $ 355,946  
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable   $ 4,518     $ 3,734  
Accrued liabilities     5,779       6,497  
Deferred rent, current     398       391  
Total current liabilities     10,695       10,622  
Deferred rent     946       1,046  
Total liabilities     11,641       11,668  
Stockholders’ Equity:                
Common stock     38       38  
Additional paid-in capital     513,539       510,309  
Accumulated other comprehensive loss     (103 )     (77 )
Accumulated deficit     (191,998 )     (165,992 )
Total stockholders’ equity     321,476       344,278  
Total liabilities and stockholders’ equity   $ 333,117     $ 355,946  


Investor Contacts:
Jennifer Lew, Chief Financial Officer
Annexon Biosciences

Sara Michelmore

Media Contacts:
Miriam Mason
Annexon Biosciences

« back to news page